AGIO Q2 Earnings Lag, Stock Down on Missing Pediatric Study Goal
AGIOAgios Pharmaceuticals(AGIO) ZACKS·2024-08-02 23:46

Agios Pharmaceuticals (AGIO) reported a loss of 1.69pershareinsecond−quarter2024,widerthantheZacksConsensusEstimateofalossof1.69 per share in second-quarter 2024, wider than the Zacks Consensus Estimate of a loss of 1.58. In the year-ago quarter, the company reported a loss of 1.51.AGIOreportedrevenuesof1.51.AGIO reported revenues of 8.6 million, which missed the Zacks Consensus Estimate of 9.4million.Intheyear−agoquarter,thecompanyrecordedrevenuesof9.4 million. In the year-ago quarter, the company recorded revenues of 6.7 million.Quarter in DetailIn the reported quarter, revenues were generated entirely from product revenues of Agios’ only marketed drug, Pyruk ...